Analysts Issue Forecasts for Teladoc Health Q1 Earnings

Teladoc Health, Inc. (NYSE:TDOC) – Stock analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Teladoc Health in a research note issued on Wednesday, October 30th. Leerink Partnrs analyst M. Cherny expects that the health services provider will post earnings per share of ($0.31) for the quarter. The consensus estimate for Teladoc Health’s current full-year earnings is ($1.18) per share. Leerink Partnrs also issued estimates for Teladoc Health’s Q2 2025 earnings at ($0.26) EPS and Q3 2025 earnings at ($0.29) EPS.

TDOC has been the topic of several other reports. Stifel Nicolaus cut their price objective on Teladoc Health from $16.00 to $9.00 and set a “hold” rating on the stock in a research report on Thursday, August 1st. Barclays lifted their price target on Teladoc Health from $10.00 to $12.00 and gave the company an “overweight” rating in a research report on Thursday. TD Cowen decreased their price objective on Teladoc Health from $9.00 to $8.00 and set a “hold” rating for the company in a report on Thursday. Cantor Fitzgerald restated an “overweight” rating and set a $10.00 target price on shares of Teladoc Health in a report on Tuesday, August 20th. Finally, Truist Financial decreased their price target on shares of Teladoc Health from $15.00 to $10.00 and set a “hold” rating for the company in a research note on Friday, August 2nd. Fourteen investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Teladoc Health has a consensus rating of “Hold” and a consensus target price of $11.86.

Teladoc Health Price Performance

TDOC opened at $8.96 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.66 and a quick ratio of 1.62. The stock’s 50 day moving average price is $8.41 and its 200-day moving average price is $9.72. Teladoc Health has a 52-week low of $6.76 and a 52-week high of $22.54.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings results on Wednesday, October 30th. The health services provider reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.10. The business had revenue of $640.51 million for the quarter, compared to analyst estimates of $630.50 million. Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 9.40%.

Insider Activity

In other news, CMO Stephany Verstraete sold 15,000 shares of Teladoc Health stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $7.60, for a total transaction of $114,000.00. Following the completion of the sale, the chief marketing officer now owns 45,158 shares of the company’s stock, valued at approximately $343,200.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Teladoc Health news, Director Thomas Mckinley acquired 7,000 shares of the stock in a transaction that occurred on Tuesday, August 6th. The stock was bought at an average cost of $7.57 per share, with a total value of $52,990.00. Following the completion of the purchase, the director now directly owns 31,077 shares in the company, valued at $235,252.89. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Stephany Verstraete sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $7.60, for a total transaction of $114,000.00. Following the transaction, the chief marketing officer now directly owns 45,158 shares in the company, valued at $343,200.80. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 36,588 shares of company stock valued at $268,831. 0.95% of the stock is currently owned by company insiders.

Institutional Trading of Teladoc Health

Hedge funds have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Teladoc Health by 2.1% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 65,588 shares of the health services provider’s stock worth $641,000 after acquiring an additional 1,352 shares in the last quarter. Covestor Ltd grew its stake in Teladoc Health by 58.1% in the first quarter. Covestor Ltd now owns 3,817 shares of the health services provider’s stock valued at $57,000 after purchasing an additional 1,403 shares during the last quarter. Signaturefd LLC raised its holdings in Teladoc Health by 148.7% in the second quarter. Signaturefd LLC now owns 2,868 shares of the health services provider’s stock worth $28,000 after purchasing an additional 1,715 shares in the last quarter. Swiss National Bank raised its holdings in Teladoc Health by 0.6% in the first quarter. Swiss National Bank now owns 326,902 shares of the health services provider’s stock worth $4,936,000 after purchasing an additional 1,800 shares in the last quarter. Finally, Blue Trust Inc. lifted its position in shares of Teladoc Health by 84.5% during the third quarter. Blue Trust Inc. now owns 4,048 shares of the health services provider’s stock valued at $40,000 after buying an additional 1,854 shares during the last quarter. Hedge funds and other institutional investors own 76.82% of the company’s stock.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.